Your browser doesn't support javascript.
Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination.
Liu, Ya-Ting; Wang, Shang-Shang.
  • Liu YT; Department of Dermatology Huashan Hospital Fudan University Shanghai China.
  • Wang SS; Department of Dermatology Huashan Hospital Fudan University Shanghai China.
Skin Health Dis ; : e139, 2022 Jun 16.
Article in English | MEDLINE | ID: covidwho-2232649
ABSTRACT
Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67-year-old man with Pityriasis rubra pilaris might induced by COVID-19 vaccination. The patient developed the lesions after the first dose of vaccine and significantly aggravated after the second dose. He had poor effect and liver function impairment developed after acitretin used, but achieved satisfactory efficacy after replacement to ixekizumab, an interleukin-17A inhibitor.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report Topics: Vaccines Language: English Journal: Skin Health Dis Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report Topics: Vaccines Language: English Journal: Skin Health Dis Year: 2022 Document Type: Article